JP2023093495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023093495A5 JP2023093495A5 JP2023054891A JP2023054891A JP2023093495A5 JP 2023093495 A5 JP2023093495 A5 JP 2023093495A5 JP 2023054891 A JP2023054891 A JP 2023054891A JP 2023054891 A JP2023054891 A JP 2023054891A JP 2023093495 A5 JP2023093495 A5 JP 2023093495A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sequence
- phosphoinositide
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093012A JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15181925 | 2015-08-21 | ||
| EP15181925.7 | 2015-08-21 | ||
| JP2021059383A JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021059383A Division JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093012A Division JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023093495A JP2023093495A (ja) | 2023-07-04 |
| JP2023093495A5 true JP2023093495A5 (https=) | 2023-11-22 |
Family
ID=54010888
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508728A Active JP6862422B2 (ja) | 2015-08-21 | 2016-08-18 | 組み合わせおよびその使用 |
| JP2021059383A Pending JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
| JP2023054891A Pending JP2023093495A (ja) | 2015-08-21 | 2023-03-30 | 組み合わせおよびその使用 |
| JP2025093012A Pending JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508728A Active JP6862422B2 (ja) | 2015-08-21 | 2016-08-18 | 組み合わせおよびその使用 |
| JP2021059383A Pending JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093012A Pending JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11224654B2 (https=) |
| EP (2) | EP3954388A1 (https=) |
| JP (4) | JP6862422B2 (https=) |
| KR (2) | KR102786010B1 (https=) |
| CN (2) | CN107921129B (https=) |
| AU (3) | AU2016311136B2 (https=) |
| CA (1) | CA2995738A1 (https=) |
| CY (1) | CY1124706T1 (https=) |
| DK (1) | DK3337506T3 (https=) |
| ES (1) | ES2891336T3 (https=) |
| HR (1) | HRP20211291T1 (https=) |
| HU (1) | HUE056408T2 (https=) |
| IL (2) | IL257345B2 (https=) |
| LT (1) | LT3337506T (https=) |
| MX (2) | MX392561B (https=) |
| PL (1) | PL3337506T3 (https=) |
| PT (1) | PT3337506T (https=) |
| RS (1) | RS62260B1 (https=) |
| RU (1) | RU2767063C2 (https=) |
| SI (1) | SI3337506T1 (https=) |
| SM (1) | SMT202100541T1 (https=) |
| WO (1) | WO2017032679A1 (https=) |
| ZA (1) | ZA201801052B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100541T1 (it) * | 2015-08-21 | 2021-11-12 | Morphosys Ag | Combinazioni e loro usi |
| IL301786B2 (en) | 2016-10-28 | 2025-09-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses |
| HRP20231229T1 (hr) | 2017-05-31 | 2024-02-02 | Morphosys Ag | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje |
| WO2019011918A1 (en) | 2017-07-10 | 2019-01-17 | International - Drug - Development - Biotech | TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS |
| KR20200030337A (ko) * | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| EP4051317A1 (en) * | 2019-10-31 | 2022-09-07 | MorphoSys AG | Sequential anti-cd19 therapy |
| CA3203587A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| TW202334231A (zh) * | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| ES2788383T3 (es) | 2000-04-25 | 2020-10-21 | Icos Corp | Inhibidores de delta fosfatidilo-inositol 3-quinasa humana |
| CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20080152649A1 (en) * | 2002-03-01 | 2008-06-26 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| PL2383297T3 (pl) * | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| EP2398829A2 (en) | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| EP2445530B1 (en) | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| CN107227335A (zh) * | 2009-10-27 | 2017-10-03 | 安进研发（慕尼黑）股份有限公司 | 用于施用CD19xCD3双特异性抗体的给药方案 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| HUE058855T2 (hu) | 2011-08-16 | 2022-09-28 | Morphosys Ag | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával |
| PL2744515T3 (pl) | 2011-08-16 | 2022-05-30 | Morphosys Ag | Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym |
| SI2834241T1 (sl) | 2012-03-05 | 2021-06-30 | Gilead Calistoga Llc | Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| CA2900658A1 (en) | 2013-02-15 | 2014-08-21 | 3M Innovative Properties Company | System and method for making pleated filter media |
| JP2017519757A (ja) | 2014-06-16 | 2017-07-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | 慢性リンパ球性白血病（ｃｌｌ）の処置 |
| LT3302550T (lt) | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| SMT202100541T1 (it) | 2015-08-21 | 2021-11-12 | Morphosys Ag | Combinazioni e loro usi |
| RS62155B1 (sr) | 2016-05-30 | 2021-08-31 | Morphosys Ag | Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata |
| SI3475303T1 (sl) | 2016-06-27 | 2021-12-31 | Morphosys Ag | Formulacija protitelesa proti CD19 |
| IL301786B2 (en) | 2016-10-28 | 2025-09-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses |
| HRP20231229T1 (hr) | 2017-05-31 | 2024-02-02 | Morphosys Ag | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| MX2021013101A (es) | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| TWI865644B (zh) | 2019-10-31 | 2024-12-11 | 德商莫菲西斯公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| EP4051317A1 (en) | 2019-10-31 | 2022-09-07 | MorphoSys AG | Sequential anti-cd19 therapy |
| US20210130461A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| US20230014026A1 (en) | 2020-06-22 | 2023-01-19 | Morphosys Ag | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint |
| CA3203587A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| US20220184208A1 (en) | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| TW202334231A (zh) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
-
2016
- 2016-08-18 SM SM20210541T patent/SMT202100541T1/it unknown
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 IL IL297057A patent/IL297057B2/en unknown
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 CN CN202210502807.XA patent/CN115054697B/zh active Active
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 KR KR1020247011695A patent/KR102786010B1/ko active Active
- 2016-08-18 MX MX2018002241A patent/MX392561B/es unknown
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en not_active Ceased
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Ceased
-
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
-
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US12194095B2/en active Active
-
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
-
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en not_active Abandoned
- 2024-12-02 US US18/965,167 patent/US20250195646A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093012A patent/JP2025131697A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023093495A5 (https=) | ||
| RU2017143166A (ru) | Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение | |
| JP2022191301A5 (https=) | ||
| JP2019533682A5 (https=) | ||
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| JP2022119854A5 (https=) | ||
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| RU2018107929A (ru) | Комбинации и их использование | |
| JP2017048208A5 (https=) | ||
| JP2017528462A5 (https=) | ||
| JP2017507954A5 (https=) | ||
| FI3740504T3 (fi) | CD70-yhdistelmähoito | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| JP2019519770A5 (https=) | ||
| JP2017507953A5 (https=) | ||
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| PE20160999A1 (es) | Metodos para administrar anticuerpos anti-tnf-alfa | |
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| IL317199A (en) | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| JPWO2020132066A5 (https=) | ||
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma |